2 unchanged sentences
Exhibit Description
−Removed: Form of Pre-Funded Warrant (incorporated herein by reference to Exhibit 4.1 to the Current Report on Form 8-K, filed with the SEC on February 28,
−Removed: Form of Common Warrant (incorporated herein by reference to Exhibit 4.2 to the Current Report on Form 8-K, filed with the SEC on February 28, 2025).
−Removed: Form of Debenture (incorporated herein by reference to Exhibit 4.1 to the Current Report on Form 8-K, filed with the SEC on May 2, 2025).
−Removed: Form of Warrant (incorporated herein by reference to Exhibit 4.2 to the Current Report on Form 8-K, filed with the SEC on May 2, 2025).
−Removed: Form of Securities Purchase Agreement dated February 26, 2025, by and between PDS Biotechnology Corporation and the Purchasers (incorporated herein
−Removed: by reference to Exhibit 10.1 to the Current Report on Form 8-K, filed with the SEC on February 28, 2025).
−Removed: Placement Agency Agreement dated February 26, 2025, between PDS Biotechnology Corporation and A.G.P./Alliance Global Partners (incorporated herein by
−Removed: reference to Exhibit 10.2 to the Current Report on Form 8-K, filed with the SEC on February 28, 2025).
−Removed: Securities Purchase Agreement, dated April 30, 2025, by and among PDS Biotechnology Corporation, the purchasers named therein, and JGB Collateral LLC
−Removed: (incorporated herein by reference to Exhibit 10.1 to the Current Report on Form 8-K, filed with the SEC on May 2, 2025).
−Removed: Registration Rights Agreement, dated April 30, 2025, by and among PDS Biotechnology Corporation and the purchasers named therein (incorporated herein
−Removed: by reference to Exhibit 10.2 to the Current Report on Form 8-K, filed with the SEC on May 2, 2025).
−Removed: Security Agreement, dated April 30, 2025, by and among PDS Biotechnology Corporation., each of PDS Biotechnology Corporation’s specified subsidiaries
−Removed: named therein, the purchasers named therein and JGB Collateral LLC (incorporated herein by reference to Exhibit 10.3 to the Current Report on Form 8-K, filed with the SEC on May 2, 2025).
+Added: Securities Purchase Agreement, dated April 30, 2025, by and among PDS Biotechnology Corporation, the purchasers named therein, and JGB Collateral
+Added: LLC (incorporated herein by reference to Exhibit 10.1 to the Current Report on Form 8-K, filed with the SEC on May 2, 2025).
+Added: Amendment Agreement entered into as of May 20, 2025, by and among JGB Capital, L.P., JGB Partners, L.P., JGB Capital Offshore Ltd.
+Added: Opportunity Master Fund SPC – Segregated Master Portfolio B, PDS Biotechnology Corporation and JGB Collateral LLC.
+Added: Registration Rights Agreement, dated April 30, 2025, by and among PDS Biotechnology Corporation and the purchasers named therein (incorporated
+Added: herein by reference to Exhibit 10.2 to the Current Report on Form 8-K, filed with the SEC on May 2, 2025).
+Added: Security Agreement, dated April 30, 2025, by and among PDS Biotechnology Corporation., each of PDS Biotechnology Corporation’s specified
+Added: subsidiaries named therein, the purchasers named therein and JGB Collateral LLC (incorporated herein by reference to Exhibit 10.3 to the Current Report on Form 8-K, filed with the SEC on May 2, 2025).
Form of Subsidiary Guarantee (incorporated herein by reference to Exhibit 10.4 to the Current Report on Form 8-K, filed with the SEC on May 6,
−Removed: Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant
−Removed: to Section 302 of the Sarbanes-Oxley Act of 2002.
−Removed: Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant
−Removed: to Section 302 of the Sarbanes-Oxley Act of 2002.
+Added: Amendment to the Third Amended and Restated PDS Biotechnology Corporation 2014 Equity Incentive Plan (incorporated herein by reference to Exhibit
+Added: 10.1 to the Current Report on Form 8-K, filed with the SEC on June 11, 2025).
+Added: Form of Restricted Stock Units Agreement under the Third Amended and Restated PDS Biotechnology Corporation 2014 Equity Incentive Plan.
+Added: Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as adopted
+Added: pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
+Added: Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as adopted
+Added: pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
Certification of Principal Executive Officer Pursuant to 18 U.S.C.
14 unchanged sentences
Pursuant to Item 601(a)(5) of Regulation S-K, schedules have been omitted and will be furnished on a supplemental basis to the Securities and Exchange Commission upon
−Removed: Pursuant to the requirements of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned
−Removed: thereunto duly authorized.
+Added: Pursuant to the requirements of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the
+Added: undersigned thereunto duly authorized.
PDS Biotechnology Corporation
+Added: August 13, 2025
/s/ Frank Bedu-Addo
2 unchanged sentences
(Principal Executive Officer)
+Added: August 13, 2025
/s/ Lars Boesgaard
3 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.